Early phase CROs may suffer from the aftereffects of a mega-merger, CEO says

Early phase CROs may suffer from the aftereffects of a mega-merger, CEO says

May 9, 2014 – During rumors of a large pharma mega-merger, Profil Institute’s Dr. Marcus Hompesch is interviewed about opportunities and challenges for the early phase clinical research outsourcing market.
Read the full article at Outsourcing-Pharma.com »